Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 150 results for atrial fibrillation

  1. Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis (HTG592)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis in adults. This involves inserting a new valve inside a failed bioprosthetic valve to replace the faulty one without needing repeat open heart surgery.

    HealthTech guidance
    Published
    22 September 2021
    View recommendations

    Sections for HTG592

  2. PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)

    NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .

    Medtech innovation briefing
    Published
    16 October 2017

  3. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  4. What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving long-term health outcomes for people with subclinical hyperthyroidism?

    subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation, osteoporosis, dementia, and death, including...

    Research recommendation
    Published
    10 February 2020

  5. Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

    Discontinued Reference number: GID-TAG416

    Technology appraisal guidance
    Discontinued

  6. Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG770)

    Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias. This involves implanting a cardiac pacemaker that does not have leads directly into the internal wall of the heart.

    HealthTech guidance
    Published
    25 February 2026
    View recommendations

    Sections for HTG770

  7. There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275 Date issued February 2013

    Research recommendation
    Published
    9 June 2015

  8. During this appraisal it was noted that there is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275 Date issued February 2013

    Research recommendation
    Published
    10 August 2021

  9. Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (HTG325)

    Evidence-based recommendations on percutaneous closure of the patent foramen ovale for the prevention of cerebral embolic stroke. This involves placing a small device into the heart to close the hole.

    HealthTech guidance
    Published
    18 December 2013
    View recommendations

    Sections for HTG325

  10. Backing the healthtech that changes lives

    system for type 1 diabetes, an implantable cardiac monitor to detect atrial fibrillation following a stroke, and a rapid genetic test...

    News
    Last updated
    2 April 2026

  11. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA210

  12. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (HTG730)

    Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.

    HealthTech guidance
    Published
    24 October 2024
    View recommendations

    Sections for HTG730

  13. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA679

  14. Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    22 November 2023
    View recommendations

    Sections for TA931

  15. Cardiovascular risk assessment and lipid modification (QS100)

    This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    23 July 2025
    View quality statements

    Sections for QS100